aluates Reports

$ 0.0

Automative

Global VEGF & VEGFR Inhibitor Drugs Market Research Report 2025

Published Date: June 2025

Report Code: QYRE-Auto-37F5799

Global VEGF VEGFR Inhibitor Drugs Market Insights Forecast to 2028

BUY CHAPTERS

Global VEGF & VEGFR Inhibitor Drugs Market Research Report 2025

Code: QYRE-Auto-37F5799

Report

June 2025

Pages:73

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Pfizer Inc

Novartis

GlaxoSmithKline PLC

Sanofi

Astrazeneca plc

Bristol Myers Squibb Company

Genentech, Inc. (Roche)

Merck& Co. Inc

Bayer

Eli lilly company

VEGF & VEGFR Inhibitor Drugs Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

VEGF & VEGFR Inhibitor Drugs Market

The global market for VEGF & VEGFR Inhibitor Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for VEGF & VEGFR Inhibitor Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding VEGF & VEGFR Inhibitor Drugs.

The VEGF & VEGFR Inhibitor Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global VEGF & VEGFR Inhibitor Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the VEGF & VEGFR Inhibitor Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of VEGF & VEGFR Inhibitor Drugs Market Report

Report Metric	Details
Report Name	VEGF & VEGFR Inhibitor Drugs Market
CAGR	5%
Segment by Type	Tyrosine Kinase Inhibitors Monoclonal Antibodies Others
Segment by Application	Oncology Ophthalmology Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer, Novartis AG, GlaxoSmithKline plc, Sanofi, AstraZeneca plc, Bristol-Myers-Squibb Company, Genentech, Inc. (Roche), Merck & Co., Inc., Bayer AG, Eli Lilly & Company
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of VEGF & VEGFR Inhibitor Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the VEGF & VEGFR Inhibitor Drugs Market report?

Ans: The main players in the VEGF & VEGFR Inhibitor Drugs Market are Pfizer, Novartis AG, GlaxoSmithKline plc, Sanofi, AstraZeneca plc, Bristol-Myers-Squibb Company, Genentech, Inc. (Roche), Merck & Co., Inc., Bayer AG, Eli Lilly & Company

What are the Application segmentation covered in the VEGF & VEGFR Inhibitor Drugs Market report?

Ans: The Applications covered in the VEGF & VEGFR Inhibitor Drugs Market report are Oncology, Ophthalmology, Others

What are the Type segmentation covered in the VEGF & VEGFR Inhibitor Drugs Market report?

Ans: The Types covered in the VEGF & VEGFR Inhibitor Drugs Market report are Tyrosine Kinase Inhibitors, Monoclonal Antibodies, Others

Recommended Reports

Drug Delivery & Eye

Oncology & Inhibitors

Medication & Diagnostics

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global VEGF & VEGFR Inhibitor Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Tyrosine Kinase Inhibitors

1.2.3 Monoclonal Antibodies

1.2.4 Others

1.3 Market by Application

1.3.1 Global VEGF & VEGFR Inhibitor Drugs Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Oncology

1.3.3 Ophthalmology

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global VEGF & VEGFR Inhibitor Drugs Market Perspective (2020-2031)

2.2 Global VEGF & VEGFR Inhibitor Drugs Growth Trends by Region

2.2.1 Global VEGF & VEGFR Inhibitor Drugs Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 VEGF & VEGFR Inhibitor Drugs Historic Market Size by Region (2020-2025)

2.2.3 VEGF & VEGFR Inhibitor Drugs Forecasted Market Size by Region (2026-2031)

2.3 VEGF & VEGFR Inhibitor Drugs Market Dynamics

2.3.1 VEGF & VEGFR Inhibitor Drugs Industry Trends

2.3.2 VEGF & VEGFR Inhibitor Drugs Market Drivers

2.3.3 VEGF & VEGFR Inhibitor Drugs Market Challenges

2.3.4 VEGF & VEGFR Inhibitor Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top VEGF & VEGFR Inhibitor Drugs Players by Revenue

3.1.1 Global Top VEGF & VEGFR Inhibitor Drugs Players by Revenue (2020-2025)

3.1.2 Global VEGF & VEGFR Inhibitor Drugs Revenue Market Share by Players (2020-2025)

3.2 Global VEGF & VEGFR Inhibitor Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by VEGF & VEGFR Inhibitor Drugs Revenue

3.4 Global VEGF & VEGFR Inhibitor Drugs Market Concentration Ratio

3.4.1 Global VEGF & VEGFR Inhibitor Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by VEGF & VEGFR Inhibitor Drugs Revenue in 2024

3.5 Global Key Players of VEGF & VEGFR Inhibitor Drugs Head office and Area Served

3.6 Global Key Players of VEGF & VEGFR Inhibitor Drugs, Product and Application

3.7 Global Key Players of VEGF & VEGFR Inhibitor Drugs, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 VEGF & VEGFR Inhibitor Drugs Breakdown Data by Type

4.1 Global VEGF & VEGFR Inhibitor Drugs Historic Market Size by Type (2020-2025)

4.2 Global VEGF & VEGFR Inhibitor Drugs Forecasted Market Size by Type (2026-2031)

5 VEGF & VEGFR Inhibitor Drugs Breakdown Data by Application

5.1 Global VEGF & VEGFR Inhibitor Drugs Historic Market Size by Application (2020-2025)

5.2 Global VEGF & VEGFR Inhibitor Drugs Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America VEGF & VEGFR Inhibitor Drugs Market Size (2020-2031)

6.2 North America VEGF & VEGFR Inhibitor Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America VEGF & VEGFR Inhibitor Drugs Market Size by Country (2020-2025)

6.4 North America VEGF & VEGFR Inhibitor Drugs Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe VEGF & VEGFR Inhibitor Drugs Market Size (2020-2031)

7.2 Europe VEGF & VEGFR Inhibitor Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe VEGF & VEGFR Inhibitor Drugs Market Size by Country (2020-2025)

7.4 Europe VEGF & VEGFR Inhibitor Drugs Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific VEGF & VEGFR Inhibitor Drugs Market Size (2020-2031)

8.2 Asia-Pacific VEGF & VEGFR Inhibitor Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific VEGF & VEGFR Inhibitor Drugs Market Size by Region (2020-2025)

8.4 Asia-Pacific VEGF & VEGFR Inhibitor Drugs Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America VEGF & VEGFR Inhibitor Drugs Market Size (2020-2031)

9.2 Latin America VEGF & VEGFR Inhibitor Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America VEGF & VEGFR Inhibitor Drugs Market Size by Country (2020-2025)

9.4 Latin America VEGF & VEGFR Inhibitor Drugs Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa VEGF & VEGFR Inhibitor Drugs Market Size (2020-2031)

10.2 Middle East & Africa VEGF & VEGFR Inhibitor Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa VEGF & VEGFR Inhibitor Drugs Market Size by Country (2020-2025)

10.4 Middle East & Africa VEGF & VEGFR Inhibitor Drugs Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Pfizer

11.1.1 Pfizer Company Details

11.1.2 Pfizer Business Overview

11.1.3 Pfizer VEGF & VEGFR Inhibitor Drugs Introduction

11.1.4 Pfizer Revenue in VEGF & VEGFR Inhibitor Drugs Business (2020-2025)

11.1.5 Pfizer Recent Development

11.2 Novartis AG

11.2.1 Novartis AG Company Details

11.2.2 Novartis AG Business Overview

11.2.3 Novartis AG VEGF & VEGFR Inhibitor Drugs Introduction

11.2.4 Novartis AG Revenue in VEGF & VEGFR Inhibitor Drugs Business (2020-2025)

11.2.5 Novartis AG Recent Development

11.3 GlaxoSmithKline plc

11.3.1 GlaxoSmithKline plc Company Details

11.3.2 GlaxoSmithKline plc Business Overview

11.3.3 GlaxoSmithKline plc VEGF & VEGFR Inhibitor Drugs Introduction

11.3.4 GlaxoSmithKline plc Revenue in VEGF & VEGFR Inhibitor Drugs Business (2020-2025)

11.3.5 GlaxoSmithKline plc Recent Development

11.4 Sanofi

11.4.1 Sanofi Company Details

11.4.2 Sanofi Business Overview

11.4.3 Sanofi VEGF & VEGFR Inhibitor Drugs Introduction

11.4.4 Sanofi Revenue in VEGF & VEGFR Inhibitor Drugs Business (2020-2025)

11.4.5 Sanofi Recent Development

11.5 AstraZeneca plc

11.5.1 AstraZeneca plc Company Details

11.5.2 AstraZeneca plc Business Overview

11.5.3 AstraZeneca plc VEGF & VEGFR Inhibitor Drugs Introduction

11.5.4 AstraZeneca plc Revenue in VEGF & VEGFR Inhibitor Drugs Business (2020-2025)

11.5.5 AstraZeneca plc Recent Development

11.6 Bristol-Myers-Squibb Company

11.6.1 Bristol-Myers-Squibb Company Company Details

11.6.2 Bristol-Myers-Squibb Company Business Overview

11.6.3 Bristol-Myers-Squibb Company VEGF & VEGFR Inhibitor Drugs Introduction

11.6.4 Bristol-Myers-Squibb Company Revenue in VEGF & VEGFR Inhibitor Drugs Business (2020-2025)

11.6.5 Bristol-Myers-Squibb Company Recent Development

11.7 Genentech, Inc. (Roche)

11.7.1 Genentech, Inc. (Roche) Company Details

11.7.2 Genentech, Inc. (Roche) Business Overview

11.7.3 Genentech, Inc. (Roche) VEGF & VEGFR Inhibitor Drugs Introduction

11.7.4 Genentech, Inc. (Roche) Revenue in VEGF & VEGFR Inhibitor Drugs Business (2020-2025)

11.7.5 Genentech, Inc. (Roche) Recent Development

11.8 Merck & Co., Inc.

11.8.1 Merck & Co., Inc. Company Details

11.8.2 Merck & Co., Inc. Business Overview

11.8.3 Merck & Co., Inc. VEGF & VEGFR Inhibitor Drugs Introduction

11.8.4 Merck & Co., Inc. Revenue in VEGF & VEGFR Inhibitor Drugs Business (2020-2025)

11.8.5 Merck & Co., Inc. Recent Development

11.9 Bayer AG

11.9.1 Bayer AG Company Details

11.9.2 Bayer AG Business Overview

11.9.3 Bayer AG VEGF & VEGFR Inhibitor Drugs Introduction

11.9.4 Bayer AG Revenue in VEGF & VEGFR Inhibitor Drugs Business (2020-2025)

11.9.5 Bayer AG Recent Development

11.10 Eli Lilly & Company

11.10.1 Eli Lilly & Company Company Details

11.10.2 Eli Lilly & Company Business Overview

11.10.3 Eli Lilly & Company VEGF & VEGFR Inhibitor Drugs Introduction

11.10.4 Eli Lilly & Company Revenue in VEGF & VEGFR Inhibitor Drugs Business (2020-2025)

11.10.5 Eli Lilly & Company Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Pfizer Inc

Novartis

GlaxoSmithKline PLC

Sanofi

Astrazeneca plc

Bristol Myers Squibb Company

Genentech, Inc. (Roche)

Merck& Co. Inc

Bayer

Eli lilly company

List of Tables

Table 1. Global VEGF & VEGFR Inhibitor Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Tyrosine Kinase Inhibitors

Table 3. Key Players of Monoclonal Antibodies

Table 4. Key Players of Others

Table 5. Global VEGF & VEGFR Inhibitor Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global VEGF & VEGFR Inhibitor Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global VEGF & VEGFR Inhibitor Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 8. Global VEGF & VEGFR Inhibitor Drugs Market Share by Region (2020-2025)

Table 9. Global VEGF & VEGFR Inhibitor Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 10. Global VEGF & VEGFR Inhibitor Drugs Market Share by Region (2026-2031)

Table 11. VEGF & VEGFR Inhibitor Drugs Market Trends

Table 12. VEGF & VEGFR Inhibitor Drugs Market Drivers

Table 13. VEGF & VEGFR Inhibitor Drugs Market Challenges

Table 14. VEGF & VEGFR Inhibitor Drugs Market Restraints

Table 15. Global VEGF & VEGFR Inhibitor Drugs Revenue by Players (2020-2025) & (US$ Million)

Table 16. Global VEGF & VEGFR Inhibitor Drugs Market Share by Players (2020-2025)

Table 17. Global Top VEGF & VEGFR Inhibitor Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in VEGF & VEGFR Inhibitor Drugs as of 2024)

Table 18. Ranking of Global Top VEGF & VEGFR Inhibitor Drugs Companies by Revenue (US$ Million) in 2024

Table 19. Global 5 Largest Players Market Share by VEGF & VEGFR Inhibitor Drugs Revenue (CR5 and HHI) & (2020-2025)

Table 20. Global Key Players of VEGF & VEGFR Inhibitor Drugs, Headquarters and Area Served

Table 21. Global Key Players of VEGF & VEGFR Inhibitor Drugs, Product and Application

Table 22. Global Key Players of VEGF & VEGFR Inhibitor Drugs, Date of Enter into This Industry

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global VEGF & VEGFR Inhibitor Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 25. Global VEGF & VEGFR Inhibitor Drugs Revenue Market Share by Type (2020-2025)

Table 26. Global VEGF & VEGFR Inhibitor Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 27. Global VEGF & VEGFR Inhibitor Drugs Revenue Market Share by Type (2026-2031)

Table 28. Global VEGF & VEGFR Inhibitor Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 29. Global VEGF & VEGFR Inhibitor Drugs Revenue Market Share by Application (2020-2025)

Table 30. Global VEGF & VEGFR Inhibitor Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 31. Global VEGF & VEGFR Inhibitor Drugs Revenue Market Share by Application (2026-2031)

Table 32. North America VEGF & VEGFR Inhibitor Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 33. North America VEGF & VEGFR Inhibitor Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 34. North America VEGF & VEGFR Inhibitor Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 35. Europe VEGF & VEGFR Inhibitor Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 36. Europe VEGF & VEGFR Inhibitor Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 37. Europe VEGF & VEGFR Inhibitor Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 38. Asia-Pacific VEGF & VEGFR Inhibitor Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 39. Asia-Pacific VEGF & VEGFR Inhibitor Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 40. Asia-Pacific VEGF & VEGFR Inhibitor Drugs Market Size by Region (2026-2031) & (US$ Million)

Table 41. Latin America VEGF & VEGFR Inhibitor Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 42. Latin America VEGF & VEGFR Inhibitor Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 43. Latin America VEGF & VEGFR Inhibitor Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 44. Middle East & Africa VEGF & VEGFR Inhibitor Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 45. Middle East & Africa VEGF & VEGFR Inhibitor Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 46. Middle East & Africa VEGF & VEGFR Inhibitor Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 47. Pfizer Company Details

Table 48. Pfizer Business Overview

Table 49. Pfizer VEGF & VEGFR Inhibitor Drugs Product

Table 50. Pfizer Revenue in VEGF & VEGFR Inhibitor Drugs Business (2020-2025) & (US$ Million)

Table 51. Pfizer Recent Development

Table 52. Novartis AG Company Details

Table 53. Novartis AG Business Overview

Table 54. Novartis AG VEGF & VEGFR Inhibitor Drugs Product

Table 55. Novartis AG Revenue in VEGF & VEGFR Inhibitor Drugs Business (2020-2025) & (US$ Million)

Table 56. Novartis AG Recent Development

Table 57. GlaxoSmithKline plc Company Details

Table 58. GlaxoSmithKline plc Business Overview

Table 59. GlaxoSmithKline plc VEGF & VEGFR Inhibitor Drugs Product

Table 60. GlaxoSmithKline plc Revenue in VEGF & VEGFR Inhibitor Drugs Business (2020-2025) & (US$ Million)

Table 61. GlaxoSmithKline plc Recent Development

Table 62. Sanofi Company Details

Table 63. Sanofi Business Overview

Table 64. Sanofi VEGF & VEGFR Inhibitor Drugs Product

Table 65. Sanofi Revenue in VEGF & VEGFR Inhibitor Drugs Business (2020-2025) & (US$ Million)

Table 66. Sanofi Recent Development

Table 67. AstraZeneca plc Company Details

Table 68. AstraZeneca plc Business Overview

Table 69. AstraZeneca plc VEGF & VEGFR Inhibitor Drugs Product

Table 70. AstraZeneca plc Revenue in VEGF & VEGFR Inhibitor Drugs Business (2020-2025) & (US$ Million)

Table 71. AstraZeneca plc Recent Development

Table 72. Bristol-Myers-Squibb Company Company Details

Table 73. Bristol-Myers-Squibb Company Business Overview

Table 74. Bristol-Myers-Squibb Company VEGF & VEGFR Inhibitor Drugs Product

Table 75. Bristol-Myers-Squibb Company Revenue in VEGF & VEGFR Inhibitor Drugs Business (2020-2025) & (US$ Million)

Table 76. Bristol-Myers-Squibb Company Recent Development

Table 77. Genentech, Inc. (Roche) Company Details

Table 78. Genentech, Inc. (Roche) Business Overview

Table 79. Genentech, Inc. (Roche) VEGF & VEGFR Inhibitor Drugs Product

Table 80. Genentech, Inc. (Roche) Revenue in VEGF & VEGFR Inhibitor Drugs Business (2020-2025) & (US$ Million)

Table 81. Genentech, Inc. (Roche) Recent Development

Table 82. Merck & Co., Inc. Company Details

Table 83. Merck & Co., Inc. Business Overview

Table 84. Merck & Co., Inc. VEGF & VEGFR Inhibitor Drugs Product

Table 85. Merck & Co., Inc. Revenue in VEGF & VEGFR Inhibitor Drugs Business (2020-2025) & (US$ Million)

Table 86. Merck & Co., Inc. Recent Development

Table 87. Bayer AG Company Details

Table 88. Bayer AG Business Overview

Table 89. Bayer AG VEGF & VEGFR Inhibitor Drugs Product

Table 90. Bayer AG Revenue in VEGF & VEGFR Inhibitor Drugs Business (2020-2025) & (US$ Million)

Table 91. Bayer AG Recent Development

Table 92. Eli Lilly & Company Company Details

Table 93. Eli Lilly & Company Business Overview

Table 94. Eli Lilly & Company VEGF & VEGFR Inhibitor Drugs Product

Table 95. Eli Lilly & Company Revenue in VEGF & VEGFR Inhibitor Drugs Business (2020-2025) & (US$ Million)

Table 96. Eli Lilly & Company Recent Development

Table 97. Research Programs/Design for This Report

Table 98. Key Data Information from Secondary Sources

Table 99. Key Data Information from Primary Sources

Table 100. Authors List of This Report

List of Figures

Figure 1. VEGF & VEGFR Inhibitor Drugs Picture

Figure 2. Global VEGF & VEGFR Inhibitor Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global VEGF & VEGFR Inhibitor Drugs Market Share by Type: 2024 VS 2031

Figure 4. Tyrosine Kinase Inhibitors Features

Figure 5. Monoclonal Antibodies Features

Figure 6. Others Features

Figure 7. Global VEGF & VEGFR Inhibitor Drugs Market Size by Application (2020-2031) & (US$ Million)

Figure 8. Global VEGF & VEGFR Inhibitor Drugs Market Share by Application: 2024 VS 2031

Figure 9. Oncology Case Studies

Figure 10. Ophthalmology Case Studies

Figure 11. Others Case Studies

Figure 12. VEGF & VEGFR Inhibitor Drugs Report Years Considered

Figure 13. Global VEGF & VEGFR Inhibitor Drugs Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 14. Global VEGF & VEGFR Inhibitor Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 15. Global VEGF & VEGFR Inhibitor Drugs Market Share by Region: 2024 VS 2031

Figure 16. Global VEGF & VEGFR Inhibitor Drugs Market Share by Players in 2024

Figure 17. Global Top VEGF & VEGFR Inhibitor Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in VEGF & VEGFR Inhibitor Drugs as of 2024)

Figure 18. The Top 10 and 5 Players Market Share by VEGF & VEGFR Inhibitor Drugs Revenue in 2024

Figure 19. North America VEGF & VEGFR Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 20. North America VEGF & VEGFR Inhibitor Drugs Market Share by Country (2020-2031)

Figure 21. United States VEGF & VEGFR Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Canada VEGF & VEGFR Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe VEGF & VEGFR Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe VEGF & VEGFR Inhibitor Drugs Market Share by Country (2020-2031)

Figure 25. Germany VEGF & VEGFR Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. France VEGF & VEGFR Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. U.K. VEGF & VEGFR Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Italy VEGF & VEGFR Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Russia VEGF & VEGFR Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Nordic Countries VEGF & VEGFR Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific VEGF & VEGFR Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific VEGF & VEGFR Inhibitor Drugs Market Share by Region (2020-2031)

Figure 33. China VEGF & VEGFR Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Japan VEGF & VEGFR Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. South Korea VEGF & VEGFR Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Southeast Asia VEGF & VEGFR Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. India VEGF & VEGFR Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Australia VEGF & VEGFR Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America VEGF & VEGFR Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America VEGF & VEGFR Inhibitor Drugs Market Share by Country (2020-2031)

Figure 41. Mexico VEGF & VEGFR Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Brazil VEGF & VEGFR Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa VEGF & VEGFR Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa VEGF & VEGFR Inhibitor Drugs Market Share by Country (2020-2031)

Figure 45. Turkey VEGF & VEGFR Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Saudi Arabia VEGF & VEGFR Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. UAE VEGF & VEGFR Inhibitor Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Pfizer Revenue Growth Rate in VEGF & VEGFR Inhibitor Drugs Business (2020-2025)

Figure 49. Novartis AG Revenue Growth Rate in VEGF & VEGFR Inhibitor Drugs Business (2020-2025)

Figure 50. GlaxoSmithKline plc Revenue Growth Rate in VEGF & VEGFR Inhibitor Drugs Business (2020-2025)

Figure 51. Sanofi Revenue Growth Rate in VEGF & VEGFR Inhibitor Drugs Business (2020-2025)

Figure 52. AstraZeneca plc Revenue Growth Rate in VEGF & VEGFR Inhibitor Drugs Business (2020-2025)

Figure 53. Bristol-Myers-Squibb Company Revenue Growth Rate in VEGF & VEGFR Inhibitor Drugs Business (2020-2025)

Figure 54. Genentech, Inc. (Roche) Revenue Growth Rate in VEGF & VEGFR Inhibitor Drugs Business (2020-2025)

Figure 55. Merck & Co., Inc. Revenue Growth Rate in VEGF & VEGFR Inhibitor Drugs Business (2020-2025)

Figure 56. Bayer AG Revenue Growth Rate in VEGF & VEGFR Inhibitor Drugs Business (2020-2025)

Figure 57. Eli Lilly & Company Revenue Growth Rate in VEGF & VEGFR Inhibitor Drugs Business (2020-2025)

Figure 58. Bottom-up and Top-down Approaches for This Report

Figure 59. Data Triangulation

Figure 60. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Anti VEGF Medicine Market Research Report 2024

Anti vascular Endothelial Growth Factor Anti VEGF Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global VEGF Targeted Drugs for Breast Cancer Market Research Report 2024

Global Targeted Drug VEGFR2 Inhibitors for NSCLC Market Research Report 2024

Global Targeted Drug VEGF Inhibitors for NSCLC Market Research Report 2024

Cardiovascular Therapeutic Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Cardiovascular Disease Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Pharmaceutical Retail Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Drug Pharmaceuticals Cosmetics Retail Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

AI for Cancer Diagnosis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Anti Hypertensive Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Cardiac Medication Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Bevacizumab Biosimilar Market

Global Ophthalmology AI assisted Diagnosis Software Market Research Report 2024

Cholesterol Reducer Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

AI Drug Development Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Pharmaceutical Asset Managements Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Cardiovascular Drug Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Cardiovascular Disease Nursing Drugs Market Research Report 2025

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions